Analyst firms · Leerink Partners · VCYT
Leerink Partners VCYT price target and rating history
Veracyte Inc. (VCYT) · Health Care
Leerink Partners rates Veracyte Inc. (VCYT) Market Perform with a $35 price target, as of its latest action on Nov 5, 2026. It has published 4 rating actions on VCYT since July 2021, including 0 upgrades and 1 downgrade. Across 5 firms with a VCYT price target in the last 12 months, the median target is $48. Leerink Partners's $35 is 27% below that.
- Current rating
- Market Perform
- Price target
- $35
- Median target, all firms
- $48
- Actions on VCYT
- 4
Leerink Partners price target on VCYT
Every Leerink Partners rating on VCYT
- Nov 5, 2026
- Mar 1, 2022
- Jul 30, 2021
- Jul 14, 2021
How other firms rate VCYT
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Leerink Partners | Market Perform | $35 | Nov 5, 2026 |
| Piper Sandler | Overweight | $66 | Jul 15, 2026 |
| Wolfe Research | Outperform | $55 | Jun 2, 2026 |
| Jefferies | Buy | $45 | Apr 13, 2026 |
| Morgan Stanley | Underweight | $48 | Dec 2, 2025 |
Questions about Leerink Partners and VCYT
- What is Leerink Partners's price target for VCYT?
- Leerink Partners's latest stated price target for Veracyte Inc. (VCYT) is $35, from its action on Nov 5, 2026.
- What is Leerink Partners's rating on VCYT?
- Leerink Partners rates VCYT Market Perform, a neutral rating, as of Nov 5, 2026.
- When did Leerink Partners last change its view on VCYT?
- On Nov 5, 2026, Leerink Partners downgrades to Market Perform from Outperform, price target $35.
- How does Leerink Partners's VCYT target compare with other analysts?
- Across 5 firms with a VCYT price target in the last 12 months, the median target is $48. Leerink Partners's $35 is 27% below that.
More VCYT rating histories
All Leerink Partners ratingsVCYT news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.